Piper Sandler Maintains Overweight on DexCom, Lowers Price Target to $90
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Matt O'Brien maintains an Overweight rating on DexCom (NASDAQ:DXCM) but lowers the price target from $150 to $90.
July 26, 2024 | 1:36 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Piper Sandler analyst Matt O'Brien maintains an Overweight rating on DexCom but lowers the price target from $150 to $90.
The lowered price target from $150 to $90 suggests a significant reduction in expected future performance, which could negatively impact investor sentiment and short-term stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100